#CCTG and #CancerResearchInstitute announce the first patient enrolled in a new sub-study for the #IPROC ovarian cancer #immunotherapy platform trial - a new #immunotherapy combination and patient population, accelerating progress toward more effective ovarian cancer treatments. buff.ly/rQWkoeZ